WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this review process, Aerovate has engaged Wedbush PacGrow as the c ...

Core Viewpoint - Aerovate Therapeutics, Inc. is halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) and will conduct a comprehensive review of strategic alternatives to maximize shareholder value [1][2] Group 1 - The company has engaged Wedbush PacGrow as its exclusive strategic financial advisor to assist in exploring various strategic alternatives, which may include acquisition, merger, reverse merger, business combination, liquidation, or other transactions [2] - There is no assurance that the review process will lead to a transaction or that any pursued transaction will be completed on attractive terms [2] - Aerovate has not set a timetable for the completion of this review process and will not comment further until a definitive course of action is approved by the Board of Directors or the review process is concluded [2]

ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. ("Aerovate" or the "Company") (NASDAQ:AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that "the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension ("PVR") compared to placebo for a ...

ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that “the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension (“PVR”) compared to placebo for ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (Nasdaq: AVTE) investors that a class action has been filed on behalf of investors. Aerovate investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley ...

Aerovate Therapeutics’ (AVTE) shares plummeted 93.3% in the last trading session on Jun 17 after the company announced disappointing top-line results from the mid-stage portion of the IIb/III IMPAHCT study evaluating its lead candidate, AV-101, in adults with pulmonary arterial hypertension (PAH).The mid to late-stage IMPAHCT study evaluated the efficacy, safety and tolerability of three different doses of AV-101 compared with placebo.Per the data readout from the phase IIb portion of the IMPAHCT study, AV- ...

WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH). The objective of the Phase 2b portion of IMPAHCT was to assess the efficacy, ...

WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH). The objective of the Phase 2b portion of IMPAHCT was to assess the efficacy ...

Solskin Aerovate Therapeutics, Inc. (NASDAQ:AVTE) is developing a drug known as AV-101, which is being used to treat patients with pulmonary arterial hypertension [PAH]. The use of this inhaled drug is being explored in the ongoing phase 2b/3 IMPAHCT trial. Speaking of inhaled drug, this is highly promising. The reason why I say that is because AV-101 is an inhaled version of imatinib. It had done well in clinical trial when given to patients orally, but the problem was systemic side effects. This is wh ...

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today presented a pos ...